Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for ... Read More
06
Oct2015
30
Sep2015
Report 4: PLA Perspectives, Comparison and Contrast
Last week Manulife introduced its new DrugWatch™. It has been described by Manulife as the only program of its kind in Canada which “closely monitors the drug landscape and analyzes the effectiveness and financial impact of new medications, to ensure you receive value ... Read More
17
Sep2015
Report 3: Experience Negotiating Private Payer PLAs
PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this survey, which was conducted ... Read More
09
Sep2015
Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA
PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this ... Read More
03
Sep2015
Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA
PDCI Market Access (PDCI) and H3 Consulting (H3) conducted an online survey of a select group of Canadian pharmaceutical manufacturer and private payer stakeholders to provide clarity on the evolving private payer product listing agreement (PLA) landscape. We thank ... Read More
31
Jul2015
Topics covered in the NEWSletter include:
Soliris Pre-Hearing Conference
New Staff Member – Legal Services
Update: Compendium of Policies, Guidelines and Procedures
Part C – Guidelines and Procedures
Schedule 9 – CPI-Adjustment Methodology
Schedule 2 – Comparable Dosage Forms
2016 HDAP Meeting Schedule & Filing Requirements:
February 29
May 2
September 12
November 28
PMPRB Transition to Canada.ca
Update: Germany Recognized Price Source
Summary ... Read More
27
Jul2015
Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable.
Proposed amendments ... Read More
20
Jul2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses
As noted in the June 24th TargetPharma, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are collaborating on a survey to gauge the interest, expectations, and experience associated with private payer product listing agreements (PLAs).
Surveys ... Read More
24
Jun2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations
Private payers – the community of insurers, Pharmacy Benefit Managers (PBMs) and employers in Canada – are starting to build internal competencies aimed at negotiating product listing agreements (PLAs) with pharmaceutical companies. For the past several years, private ... Read More
23
Jun2015
Currently in Canada, switching and substitutability between originator biologics and biosimilars has not been established, however that is not the case internationally. Earlier this year the Dutch Medicines Evaluation Board (MEB) supported switching patients from an innovator biologic to a biosimilar, so long as health professionals are involved and the ... Read More